ALX Oncology Holdings Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: ALXO · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1810182
Sentiment: neutral
Topics: ALX Oncology, Annual Meeting, Proxy Statement, Virtual Meeting, Director Election
TL;DR
<b>ALX Oncology Holdings Inc. invites stockholders to its virtual 2024 Annual Meeting on June 12, 2024, to elect directors and vote on company matters.</b>
AI Summary
ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. ALX Oncology Holdings Inc. will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 1:00 p.m. Pacific Time. The meeting will be conducted virtually via a live webcast at www.virtualshareholdermeeting.com/ALXO2024. Stockholders can listen live, submit questions, and vote online during the meeting. The agenda includes the election of three Class I directors to serve until the 2027 annual meeting. The company urges stockholders to vote their shares promptly via Internet, phone, or mail.
Why It Matters
For investors and stakeholders tracking ALX ONCOLOGY HOLDINGS INC, this filing contains several important signals. The virtual format allows for broader participation and accessibility for stockholders regardless of location. The election of directors is a critical governance function, ensuring the board's composition aligns with the company's strategic direction.
Risk Assessment
Risk Level: low — ALX ONCOLOGY HOLDINGS INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
Analyst Insight
Stockholders should review the proxy materials carefully to understand the director nominees and any other proposals before voting.
Key Numbers
- June 12, 2024 — Annual Meeting Date (2024 Annual Meeting of Stockholders date)
- 1:00 p.m. Pacific Time — Annual Meeting Time (2024 Annual Meeting of Stockholders time)
- 3 — Directors to be Elected (Number of Class I directors to be elected)
- 2027 — Director Term End (Year until which elected directors will serve)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant name
- June 12, 2024 (date) — Date of Annual Meeting
- 1:00 p.m. Pacific Time (time) — Time of Annual Meeting
- www.virtualshareholdermeeting.com/ALXO2024 (url) — Virtual meeting link
- Corey Goodman, Ph.D. (person) — Executive Chairman of the Board of Directors
- Jason Lettmann (person) — Chief Executive Officer and Director
- 2027 (date) — Director term end year
- 323 Allerton Avenue (address) — Company business address
FAQ
When did ALX ONCOLOGY HOLDINGS INC file this DEF 14A?
ALX ONCOLOGY HOLDINGS INC filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ALX ONCOLOGY HOLDINGS INC (ALXO).
Where can I read the original DEF 14A filing from ALX ONCOLOGY HOLDINGS INC?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ALX ONCOLOGY HOLDINGS INC.
What are the key takeaways from ALX ONCOLOGY HOLDINGS INC's DEF 14A?
ALX ONCOLOGY HOLDINGS INC filed this DEF 14A on April 22, 2024. Key takeaways: ALX Oncology Holdings Inc. will hold its 2024 Annual Meeting of Stockholders on June 12, 2024, at 1:00 p.m. Pacific Time.. The meeting will be conducted virtually via a live webcast at www.virtualshareholdermeeting.com/ALXO2024.. Stockholders can listen live, submit questions, and vote online during the meeting..
Is ALX ONCOLOGY HOLDINGS INC a risky investment based on this filing?
Based on this DEF 14A, ALX ONCOLOGY HOLDINGS INC presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would alter the company's risk profile.
What should investors do after reading ALX ONCOLOGY HOLDINGS INC's DEF 14A?
Stockholders should review the proxy materials carefully to understand the director nominees and any other proposals before voting. The overall sentiment from this filing is neutral.
Risk Factors
- General Disclosure Requirements [low — regulatory]: The company must comply with SEC regulations for proxy solicitations, including providing accurate and complete information to stockholders.
Key Dates
- 2024-06-12: Annual Meeting of Stockholders — Key date for stockholder voting and director elections.
Glossary
- DEF 14A
- Definitive Proxy Statement filed with the SEC. (This filing type indicates the company is providing final proxy materials to shareholders for an upcoming meeting.)
- Proxy Statement
- A document filed by a company with the SEC that contains information that shareholders need to make informed decisions about matters to be voted on at a shareholder meeting. (Essential for understanding the proposals, director nominees, and voting procedures for the annual meeting.)
Filing Stats: 4,828 words · 19 min read · ~16 pages · Grade level 11.1 · Accepted 2024-04-22 16:01:04
Filing Documents
- alxo_def_14a_2024_proxy.htm (DEF 14A) — 1073KB
- img142714151_0.jpg (GRAPHIC) — 145KB
- img142714151_1.jpg (GRAPHIC) — 5KB
- img142714151_2.jpg (GRAPHIC) — 9KB
- img142714151_3.jpg (GRAPHIC) — 9KB
- img142714151_4.jpg (GRAPHIC) — 53KB
- img142714151_5.jpg (GRAPHIC) — 56KB
- img142714151_6.jpg (GRAPHIC) — 125KB
- img142714151_7.jpg (GRAPHIC) — 132KB
- 0000950170-24-046410.txt ( ) — 1801KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 30 Named Executive Officers 30 Summary 30 Compensation Philosophy 31 “Say-on-Pay” Voting 31 Pay Components 32 Severance and Change in Control Protections 33 Other Compensation 33 Additional Policies and Practices 34 Summary Compensation Table 35 Outstanding Equity Awards at 2023 Year-End 36 Executive Employment Letter Agreements 37 Change in Control and Severance Agreements 38 Executive Incentive Compensation Plan 39 Equity Compensation Plan Information 40 Compensation Recovery (Clawback) 41 Pay Versus Performance 41
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 46 CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS 49 Investors’ Rights Agreement 49 venBio Consulting Agreement 49 Tallac Therapeutics Agreements 49 Acquisition of ScalmiBio, Inc. 50 Indemnification Agreements 50 Related-Party Transaction Policy 50 OTHER MATTERS 51 Delinquent Section 16(a) Reports 51 Fiscal Year 2023 Annual Report and SEC Filings 51 ALX ONCOLOGY HOLDINGS INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 1:00 p.m. Pacific Time on Wednesday, June 12, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors for use at the 2024 annual meeting of stockholders of ALX Oncology Holdings Inc. (the Annual Meeting), and any postponements, adjournments or continuations thereof. The Annual Meeting will be held on Wednesday, June 12, 2024 at 1:00 p.m. Pacific Time virtually via a live webcast. You will be able to attend the Annual Meeting virtually by visiting www.virtualshareholdermeeting.com/ALXO2024, where you will be able to listen to the meeting live, submit questions and vote online by entering the control number on your proxy card. QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING The information provided in the “question and answer” format below addresses certain frequently asked questions but is not intended to be a summary of all matters contained in this proxy statement. Please read the entire proxy statement carefully before voting your shares. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this proxy statement and references to our website address in this proxy statement are inactive textual references only. Why am I receiving these materials? Our board of directors is providing these proxy materials to you in